Genprex Boosts Its Diabetes Gene Therapy Program with the License of Additional Technology from the University of Pittsburgh

Genprex, Inc. has struck an exclusive license agreement with the University of Pittsburgh for a worldwide, exclusive license to some patent applications and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy.